Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
N/A N=498 Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmias
Cardiac Arrhythmia · Atrial Fibrillation
Primary: Compare the Diagnostic Performance of Physician Rhythm Interpretation of 1-lead ECG Generated by SkyLabs CART-I Ring and Apple Watch Versus 12-lead ECG (Gold-standard)…
N/A N=234 Dysrhythmias During General Anesthesia in Children
Arrhythmias, Cardiac
Primary: Arrhythmias During General Anesthesia in Children — 220 participants
N/A N=53 Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke
Ischemic Stroke
Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants
N/A N=86 Arrhythmia Detection In Obstructive Sleep Apnea (ADIOS)
Atrial Fibrillation · Arrhythmia · Stroke, Cardiovascular
Primary: Number of Participants With Definite Atrial Fibrillation (Defined as an Irregularly Irregular Rhythm With Absence of p Waves) — 2 Participants
N/A N=83 Effectiveness of Ripple Mapping in Atrial Tachycardia Ablation
Atrial Tachycardia
Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants
N/A N=31 Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation
Atrial Fibrillation
Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV
N/A N=38 Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
Atrial Fibrillation
Primary: Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise — -10; -13 beats per minute
N/A N=262 iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology
Atrial Fibrillation · Atrial Flutter
Primary: Rate of Recurrence of Atrial Arrhythmias — 0.132; 0.091 episodes per person-month of follow-up — p=0.05
N/A N=157 AVAI: Atrial Ventricular Arrythmia Incidence
Ventricular Tachycardia · Atrial Fibrillation
Primary: Slow Ventricular Tachycardia Episodes Devices Detected (Between 120-150 Bpm and > 30sec) Atrial Fibrillation (AF) Episodes Devices Detected (> 30 Sec) — 3778; 112; 68…
N/A N=242 The IPED (Investigation of Palpitations in the ED) Study
Presyncope · Arrhythmias, Cardiac · Tachycardia, Supraventricular
Primary: Number of Participants With Symptomatic Rhythm Detection up to 90 Days — 69; 11 Participants
Phase 4 N=67 Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study
Permanent Atrial Fibrillation
Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001
N/A N=17 Evaluation of the Use of Apple Watch Features for Identification of Cardiac Arrhythmias
Atrial Fibrillation · Arrhythmias, Cardiac · Atrial Flutter
Primary: Atrial Fibrillation or Atrial Flutter (AF) of at Least 30 Seconds Duration — 0.11 Proportion of participants
N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
N/A N=19 Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A
End Stage Renal Disease
Primary: Adherence With Proposed Interventions — 88; 90; 83; 80 Percentage of sessions
N/A N=100 A Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Number of Participants With an Identified Dysrhythmia on Baseline ECG Recording — 25; 35 Participants
N/A N=411 Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
Phase 4 N=441 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Cryptogenic Symptomatic Transient Ischemic Attack · Cryptogenic Ischemic Stroke
Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006
N/A N=55 Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…
N/A N=18 Multimodality Assessment of Ventricular Scar Arrhythmogenicity.
Ventricular Tachycardia
Primary: Electrogram Duration at Digital Twin Predicted Sites Compared to Non-predicted Sites — 77.5; 65.7 ms
N/A N=40 Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS)
Stroke
Primary: Completion of Clinical Follow-up as a Measure of Feasibility — 20; 18 participants
N/A N=107 The Dynamics of Human Atrial Fibrillation
Atrial Fibrillation · Atrial Tachyarrhythmia
Primary: Survival Free of Atrial Fibrillation — 28; 31 participants
N/A N=86 Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)
Syncope
Primary: Number of Ambulatory Patch Monitor Participants Having Significant Symptomatic Arrhythmia — 9 Participants
N/A N=129 Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Number of Participants With Freedom From Device/Procedure Related Major Adverse Events (MAEs) — 3; 126 Participants
Phase 1 N=22 Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
N/A N=63 Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
Myocardiopathies · Ischemia, Myocardial · Arrythmia
Primary: MMP-2 — 173493.4; 139012.4 pg/ml
N/A N=38 Assessing Arrhythmias After Ablation Using Implantable Recorders
Atrial Fibrillation
Primary: Arrhythmia Burden — 7; 18; 18; 5 Participants
N/A N=573 Atrial Fibrillation Algorithms Clinical Validation Study
Atrial Fibrillation
Primary: SENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF] — NA; NA; NA; 88.6 percentage of participants